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ABSTRACT 
 
Anamika Tripathi 
 
WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS OF COLORECTAL PATIENTS TO 
IDENTIFY RIGHT DRUG-RIGHT TARGET FOR POTENT EFFICACY OF TARGETED THERAPY 
 
 
Colon rectal cancer (CRC) is one of the most common cancers worldwide. It is characterized by 
the successive accumulation of mutations in genes controlling epithelial cell growth and 
differentiation leading to genomic instability. This results in the activation of proto-oncogene(K-
ras), loss of tumor suppressor gene activity and abnormality in DNA repair genes. Targeted 
therapy is a new generation of cancer treatment in which drugs attack targets which are specific 
for the cancer cell and are critical for its survival or for its malignant behavior. Survival of 
metastatic CRC patients has approximately doubled due to the development of new combinations 
of standard chemotherapy, and the innovative targeted therapies, such as monoclonal antibodies 
against epidermal growth factor receptor (EGFR) or monoclonal antibodies against vascular 
endothelial growth factor (VEGFR).The study is to exhibit the need for right drug-right target 
and provides a proof of principle for potent efficacy of molecular targeted therapy for CRC. We 
have performed the weighted gene co-expression network analysis for three different patient 
cohort treated with different targeted therapy drugs. The results demonstrates the variation across 
different treatment regime in context of transcription factor networks. New significant 
transcription factors have been identified as potential biomarker for CRC cancer including 
EP300, STAT6, ATF3, ELK1, HNF4A, JUN, TAF1, IRF1, TP53, ELF1 and YY1. The results 
provides guidance for future omic study on CRC and additional validation work for potent 
biomarker for CRC. 
1 
 
CHAPTER ONE: INTRODUCTION & BACKGROUND 
 
 
Colorectal Cancer (CRC) and Targeted Therapy 
 
Colon rectal cancer (CRC) is the cancer affecting caecum, colon and rectum. Colon 
Adenocarcinoma (COAD) is the third leading cause of cancer death among men and women in 
the United States [1, 2]. In 2016, it was estimated that 70,820 new cases of colon and rectum 
cancer in men and 63,670 cases in women in the US. CRC related death in 2016 across USA 
were estimated to be 26,020 in men and 23,170 in women [3]. The life time risk of developing 
CRC is about: 1 in 21 (4.6%) for men and  1 in 24 (4.2%)for women.  
 
Risk factors for CRC 
 
The risk factors of CRC are age, smoking, poor diet, and family history. Carcinogenesis is 
characterized by the successive accumulation of mutations in genes controlling epithelial cell 
growth and differentiation leading to genomic instability whereby widespread loss of DNA 
integrity is perpetuated [4] , such as activation of proto-oncogene (K-ras), loss of tumor 
suppressor gene activity (APC,DCC) and abnormality in DNA repair genes (hMSH2, hMLH1) 
specially HNPCC syndrome.  
Targeted Therapy 
Targeted therapy is a new generation of cancer treatment which uses drugs or other substances to 
more precisely identify and attack cancer cells. As the name suggests, targeted therapies interfere 
with specific proteins involved in tumorigenesis.  Targeted therapy drugs attack targets which are 
specific for the cancer cell and are critical for its survival or for its malignant behavior. In other 
words, targeted drugs target certain parts of cancer cells that make them different from other 
cells and they also target other cells that help cancer cells grow. Additionally, The drugs target 
certain parts of the cell and the signals that are needed for a cancer to develop and keep growing. 
Therefore, targeted therapy is a growing part of the treatment for many types of cancer.  
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CHAPTER TWO: LITERATURE REVIEW 
 
 
Survival of metastatic CRC patients has approximately doubled [5]. This significant 
improvement is mainly due to the development of new combinations of standard chemotherapy, 
and with the introduction of new targeted therapies, such as monoclonal antibodies against 
epidermal growth factor receptor (EGFR) or monoclonal antibodies against vascular endothelial 
growth factor (VEGFR). The chimeric IgG1monoclonal antibody cetuximab has been proven 
efficient in irinotecan-resistant metastatic CRC with response rates ranging between 8.8% when 
used in monotherapy and 22.9% when combined with irinotecan [6-8]. EGFR has been validated 
as a therapeutic target in several human tumors, including CRC [9-11]. Ligand occupancy of the 
EGFR activates the RAS/ RAF/MAPK, STAT, and PI3K/AKT signaling pathways, which 
together modulate cellular proliferation, adhesion, angiogenesis, migration, and survival [12, 13]. 
The anti-EGFR targeted antibodies cetuximab and panitumumab administered as monotherapy in 
CRC have shown response and disease stabilization rates [9, 11]. 
 
 KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene, encodes a small GTP 
binding protein that acts as a self-inactivating signal transducer by cycling from GDP- to GTP-
bound states in response to stimulation of a cell surface receptor, including EGFR [14, 15]. 
KRAS can harbor oncogenic mutations that yield a constitutively active protein. Such mutations 
are found in approximately 30% to 50% of CRC tumors and are common in other tumor types 
[16-22]. Several studies have indicated that the presence of mutant KRAS in lung and CRC 
tumors is associated with lack of response to EGFR inhibitors [23, 24]. Vascular endothelial 
growth factor (VEGF) mediates numerous changes within the tumor vasculature, including 
endothelial cell proliferation, migration, invasion, survival, chemotaxis of bone marrow-derived 
progenitor cells, vascular permeability and vasodilatation. VEGF has several important functions 
that are independent of vascular processes, including autocrine effects on tumor cell 
function(survival, migration, invasion), immune suppression, and homing of bone marrow 
progenitors to „prepare‟ an organ for subsequent metastasis [25].The anti- VEGF monoclonal 
antibody bevacizumab (Avastin, Genentech) and other VEGF-targeted therapies, showing 
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clinical benefit in patients with metastatic colorectal cancer (CRC),either as single agents or 
when combined with chemotherapy [26-28]. 
 
 One of the outstanding issues in treating cancer is the vexing heterogeneity in patient course and 
response to therapy, even in apparently similar tumors as defined by conventional criteria. Due to 
this heterogeneity, an agent targeting one particular pathway is unlikely to be effective in all 
patients. Individualized therapies that are tailored to a patient's genetic composition and tests that 
can predict which therapy he/she will respond to will be of tremendous value for CRC. 
Molecularly targeted therapies are transforming the treatment of cancer [29]. Small molecule 
inhibitors that target key enzymes on which cancer cells depend, raise the possibility of rational 
approaches to cancer therapy. This study, demonstrates the need for right drug-right target and 
provides a proof of principle for potent efficacy of molecular targeted therapy for CRC. This 
study clearly demonstrates the variation across different treatment regime in context of 
transcription factor networks. Identifying new drug targets is a critical step. However, gene 
expression data can provide a key first step toward constructing a systems level view of the 
perturbed networks in cancer cells, which can potentially help to identify key genes, networks, or 
pathways that can be therapeutically targeted [30]. However, the identification of key molecular 
targets still remains a challenge. Recent work highlights the potential for uncovering oncogenic 
pathways and molecular targets, when genomic data are analyzed at the level of gene co-
expression modules or meta-genes or when aggregated gene sets are used to assess modules 
enriched for key biological processes [29, 31, 32]. Integrating this type of data with studies in 
model systems in which modules can be studied in response to relevant molecular perturbations 
(e.g., oncogene over-expression or pharmacological inhibition) may further facilitate the 
identification and validation of novel molecular targets [33-35]. 
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CHAPTER THREE: METHODOLOGY 
 
Methodology Flow diagram  
Figure 1 gives the overall methodology of this study. 
 
 
 
 
Figure 1: Flow Diagram of Methodology   
Identify differentially expressed 
genes (Limma Package in R)
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5 
 
 
 
Step 1: Gene expression data of CRC patients, treated with targeted therapy were obtained 
from Genomic data commons data portal website and these include (i) Bevacizumab- Stage III (5 
samples); (ii) Bevacizumab – Stage IV (9 samples) and; (iii)Cetuximab (5 samples) and 10 
normal samples ( Table 1). These three cohorts are analyzed in seven steps as shown in flow 
diagram of methodology (Figure 1). 
 
Table 1:Sample information treated with targeted therapy 
 
Step 2: Identify differentially expressed (DE) genes using Limma package in R  - 
The GDC gene expression data were normalized, pre-processed and data matrix was designed. 
This data matrix includes a coefficient for the normal vs diseased type difference for two drugs 
cohorts. The core component of the limma package is the ability to fit gene-wise linear models to 
gene expression data in order to assess DE [36]. Each analysis begins with a matrix of expression 
levels, with probes/genes/exons in the rows and different samples (biological/technical 
replicates) in the columns. The linear modeling is performed in a row-wise fashion, with 
regression coefficients and standard errors either directly estimating the comparisons of interest 
or via contrasts [36]. Test-statistics are obtained for gene ranking that can be further summarized 
at the gene set level to perform gene signature/pathway-level ranking. All the linear model  were 
fitted by using lmFit function. ebays function was used to squeeze gene wise variance towards 
the common or trended variance, which reduces the number of false positives for genes with very 
small variances and improves power to detect DE for genes with larger variances.  Top scored 
Patient sample Number of 
patients 
Tumor stage Normal sample 
Bevacizumab treated 
stage-III patients 
5 Stage-III 5 
Bevacizumab treated 
stage-IV patients 
9 Stage-IV 9 
Cetuximab treated patients 
Stage-IV 
5 Stage-IV 5 
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differentially expressed genes were obtained on the basis of log fold change at p-value 
0.001(supplementary table a). 
 
Step 3: Weighted gene co-expression network analysis - Co-expression networks 
have been found useful for describing the pair-wise relationships among gene transcripts. The 
co-expression networks, refer to nodes as 'genes' and to the node significance measure GSi as the 
gene significance measure. WGCNA R-package was used to generate weighted gene co-
expression networks [37]. The WGCNA package contains a comprehensive set of functions for 
performing a correlation network analysis of large, high-dimensional data sets. Co-expression 
network analysis was performed for three patients' cohorts: 
I. bevacizumab treated stage III patients 
II. bevacizumab treated stageIV patients  
III. cetuximab treated patients 
 
3.a: Co-expression network construction - A network is fully specified by its 
adjacency matrix aij, asymmetric n × n matrix with entries in [0, 1] whose component aij encodes 
the network connection strength between nodes i and j. To calculate the adjacency matrix, an 
intermediate quantity called the co-expression similarity sij is first defined. The default method 
defines the co-expression similarity sij as the absolute value of the correlation coefficient 
between the profiles of nodes i and j: 
 
sij = |cor(xi, xj)|             Equation 1 
 
Using a thresholding procedure, the co-expression similarity is transformed into the adjacency. 
An unweighted network adjacency aij between gene expression profiles xi and xj can be defined 
by hard thresholding the co-expression similarity sij as: 
 
𝑎𝑖𝑗 =  
1   𝑖𝑓𝑠𝑖𝑗 ≥𝜏 ;
0   𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒,
      Equation 2 
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where Ʈ is the "hard" threshold parameter. Thus, two genes are linked (aij = 1) if the absolute 
correlation between their expression profiles exceeds the (hard) threshold Ʈ . The hard-
thresholding procedure is implemented in the function signumAdjacencyFunction. Weighted 
networks allow the adjacency to take on continuous values between 0 and 1. A weighed network 
adjacency can be defined by raising the co-expression similarity to a power [5,10]. 
 
 𝒂𝒊𝒋 = 𝒔𝒊𝒋
𝜷
,              Equation 3 
 
with β≥ 1. The function adjacency calculates the adjacency matrix from expression data. The 
weighted adjacency aij between two genes is proportional to their similarity on a logarithmic 
scale, log(aij) = β × log(sij). Adjacency functions for both weighted and unweighted networks 
require the user to choose threshold parameters. In this study, undirected weighted gene co-
expression networks were used. The nodes of such a network correspond  to gene expressions, 
and edges between genes are determined by the pair wise Pearson correlations between 
expressions of genes. The soft threshold β = 6 was used for scale free topology criterion. The 
package provides functions pickSoftThreshold, pickHardThreshold that assist in choosing the 
parameters, as well as the function scaleFreePlot for evaluating whether the network exhibits a 
scale free topology. Appendix Figure (i) shows a plot identifying scale free topology in gene 
expression data of patients treated with cetuximab. 
 
3.b: Module Detection: The WGCNA package [37] provides a robust set of R functions for 
constructing weighted co-expression networks.  Once the networks are constructed, modules 
were detected for each cohorts. Modules are defined as clusters of densely interconnected genes. 
WGCNA identifies gene modules using unsupervised clustering, i.e. without the use of a priori 
defined gene sets. Standard R function hclust [38] was used for hierarchical clustering. The 
branches of the hierarchical clustering dendrogram correspond to modules and can be identified 
using any branch cutting method. In this study, dynamic tree cut method was applied. The height 
and shape parameters of the dynamic tree cut method provide improved flexibility for branch 
cutting and module detection. For module detection, a relatively large minimum module size of 
30, and a medium sensitivity (deepSplit=2) to cluster splitting were selected. Unlike unweighted 
networks that use a hard threshold to dichotomize the correlation matrix, the soft thresholding of 
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weighted gene co-expression networks preserves the continuous nature of the gene co-expression 
information, leading to highly robust results. To organize genes (transcripts) into modules, the 
topological overlap measure as a robust measure of interconnectedness in a hierarchical cluster 
analysis were used [37]. The function blockwiseModules is designed to handle network 
construction and module detection in large data sets. The function first pre-clusters nodes into 
large clusters, referred to as blocks, using a variant of k-means clustering (function 
projectiveKMeans). Hierarchical clustering is applied to each block and modules are defined as 
branches of the resulting dendrogram. To synthesize the module detection results across blocks, 
an automatic module merging step (function mergeCloseModules) is performed that merges 
modules whose eigengenes are highly correlated. 
 
 Each modules were correlated with external traits and look for the most significant 
associations. Each association was color coded by the correlation value which gives a suitable 
graphical representation that helps in reading the table and see the trait association of modules. 
Associations of individual genes with trait of interest were defined by Gene Significance GS.  
For each module, a quantitative measure of module membership MM as the correlation of the 
module eigengene and the gene expression profile were defined. This allows to quantify the 
similarity of all genes on the array to every module. Using the GS and MM measures, genes that 
have a high significance as well as high module membership in each module were identified. A 
scatter plot of Gene Significance vs. Module Membership was plotted (Figure 5). 
 
Step 4: Module preservation: Module preservation statistical tests [39] were used to 
assess how well network properties of a module in one reference data set were preserved in a test 
data set (modulePreservation function in WGCNA). Preservation statistics are influenced by a 
number of variables (module size, network size, etc). A composite preservation Z-score 
(Zsummary) was used to define preservation relative to a module of randomly assigned genes 
where values 5 > Z < 10 represent moderate preservation, while Z > 10 indicated high 
preservation. The composite statistic summarized density-based and connectivity-based 
preservation statistics (Eq. 4): 
 
𝒁𝑺𝒖𝒎𝒎𝒂𝒓𝒚 =
𝒁𝒅𝒆𝒏𝒔𝒊𝒕𝒚+ 𝒁𝒄𝒐𝒏𝒏𝒆𝒄𝒕𝒊𝒗𝒊𝒕𝒚
𝟐
    Equation 4 
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Density-based measures assessed whether module nodes remained densely connected in a test 
network; connectivity-based measures defined whether intra node connectivity patterns in the 
reference network were similar to those in the test network. A separate summary p value for 
module preservation, given as the median of the log-p values for the associated permutation Z 
statistics, was calculated. Permutation tests, where the module labels of the test network were 
randomly permuted, were employed to determine the significance of the observed preservations 
test statistics. A module of randomly assigned genes, “gold” (R21) module, was prepared as a 
sham module to evaluate bias in the module preservation across species.  
Step 5: Module selection - Module selection were performed based on correlation value.  
For the present work modules were selected for all the three cohorts as they have high correlation 
values.  
 5.a: Identification of TFs - gProfiler [40] was used to identify TFs. g:Profiler studies flat 
and ranked gene lists and finds statistically significant Gene Ontology terms, pathways and other 
gene function related terms. TFs related genes were identified by using uniprot database [41] for 
top three modules of the three cohort. iRegulon, a cyoscape plug-in  was used to identify top 
significant TFs on the basis of enrichment score. 
5.b: Pathway analysis -  KEGG [42] database was used for pathway analysis. Pathway 
analysis were performed for the TFs of selected modules for all three patient cohort. 
5.c: Network visualization- Network visualization were done by cytoscape. Networks 
were exported in cytoscape [43] using  function exportNetworkToCytoscape.  
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CHAPTER FOUR: RESULTS 
 
Step 1: Data collection -  Table 1 shows the profile of the three dataset used in the study.  
Step 2: Differential gene analysis -  Limma package in R was used to identify the 
differentially expressed genes at p- value 0.001(supplementary table a). Figure 2 shows the 
profile for the differentially expressed genes identified for three cohorts: 2,724 (bevacizumab 
treated stage- III), 10,817(bevacizumab treated stage- IV) and 14,590 ( for cetuximab treated 
patients).  
 
 
 
Figure 2: Venn diagram for differentially expressed gene for bevacizumab treated stage-III, 
Bevacizumab treated stage-IV and cetuximab treated patients at p-value 0.001 
 
 
Step 3. Weighted gene co-expression network analysis - Each differentially 
expressed gene cohort was further analyzed for its coexpression network using WGCNA [37].  
 
3.a: Co-expression network -  In this study, WGCNA  was applied to 2,724, 10,817 and 
14,590 differentially expressed genes for bevacizumab treated stage-III patients', bevacizumab 
treated stage-III patients',  and  cetuximab treated patients' respectively. The co-expression 
networks of the selected genes were generated using an unsupervised co-expression relationship. 
This was initially built on the basis of the adjacency matrix of connection strengths by using 
Pearson‟s correlation coefficients for gene pairs . Figure 3 shows networks heatmap for three 
patient cohorts.  
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Figure 3: Network heatmap plots (A) bevacizumab treated stage-III patients, (B) bevacizumab 
treated stage-III patients, (C) Cetuximab treated patients 
 
3.b: Detection of co-expression modules -  Topological overlap measure was used for 
module detection. WGCNA identifies gene modules using unsupervised clustering. A co-
expression module may reflect a true biological signal (e.g. a pathway) or it may reflect noise 
(e.g. a technical artifacts, tissue contamination, or a false positive). Table 2 shows the number of 
modules and their size range for all the three group of patients and Figure 4 shows the gene co-
expression modules with different color for all the three patients cohorts. More information about 
the module color and each modules size  are mentioned in appendix table i, ii, and iii for 
bevacizumab treated stage-III, bevacizumab stage-IV and cetuximab treated patients cohort 
respectively. 
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Table 2:  Shows number of modules and modules size range for each cohort 
Patients Cohort p-value Number of modules Modules size range 
Bevacizumab treated stage-III 
CRC Patients 
0.05 9 46- 734 
Bevacizumab treated stage-IV 
CRC Patients 
0.05 53 
 
30-968 
Cetuximab treated CRC patients 0.05 8 1101 - 3860 
 
Highly correlated module genes identified by WGCNA are represented and summarized by their 
first principal component. These are referred as the module eigengene [36]. The module 
eigengenes are used to define measures of module membership which quantify how close a gene 
is to a given module. Module membership measures allow to annotate all genes on the array and 
to screen for disease related intramodular hub genes[38].Gene significance measure as a function 
GS that assigns a non-negative number to each gene; the higher GSi the more biologically 
significant is gene i (Supplementary table b). Genes with high module membership in modules 
related to traits  are natural candidates for further validation. Figure 5 shows scatter plot of Gene 
significance(GS) vs Module membership(MM) for mediumpurple module genes of bevacizumab 
treated stage-IV patients. 
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Figure 4: Gene co-expression modules color and dendrogram (A) For bevacizumab treated stage-
III patients, (B) For bevacizumab treated stage-III patients, (C) For Cetuximab treated patients 
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Figure 5: A scatterplot of Gene Significance (GS) for gender vs. Module Membership (MM) in the 
mediumpurple module of bevacizumab tretaed stage-IV patient. There is a highly significant 
correlation between GS and MM in this module 
 
Step 4: Module preservation - To establish how well the modules defined in the larger 
reference set (each cohort)  were preserved and reproducible in the test network( remaining two  
cohort), module preservation statistics were calculated for each reference-test module pair using 
a series of permutation tests for measures of module density and connectivity. Module 
preservation analysis were performed for all the three cohorts with respect to other cohorts. 
Module preservation statistics were calculated for each reference-test module pair using a series 
of permutation tests for measures of module density and connectivity. 
Bevacacizumab treated stage -III cohort:  Module preservation analysis for this 
cohort (9 modules) was performed with respect to bevacizumab treated stage-IV(52 modules)  
and cetuximab treated patients (7 modules). Only three modules of  bevacizumab treated stage -
III patients were preserved (summary Z-score>5)(appendix table iv). It was also observed that 
these three  modules are strongly preserved within the cohorts (summary Z-score >10). Table 3 
and Figure 6 show module preservation profile for bevacizumab treated stage-III patient cohort 
(test cohort) with respect to bevacizumab treated stage-IV and cetuximab treated patient cohort( 
reference cohorts). 
 
Table 3: Module preservation of bevacizumab treated stage-III patients with respect to 
bevacizumab treated stage-IV and cetuximab cohort 
Module color Module preservation with Module preservation with 
15 
 
Bevacizumab treated stage-IV Cetuximab treated patients 
Black 7 7 
Blue 2 2 
Brown 3 3 
Green 5 5 
Magenta 9 9 
Pink 8 8 
Red 6 6 
Turquoise 1 1 
Yellow 4 4 
 
 
Figure 6: Preservation z-summary and preservation median rank for the modules of bevacizumab 
treated stage-III CRC patients 
 
Bevacacizumab treated stage -IV cohort : Similarly, for this cohort, it was found that 
47 out of 53 modules were preserved in  test cohorts (summary Z-score>5), while some modules 
were  appeared specific (black, blue, darkslateblue, grey, ivory and orange) to the this cohort 
network (Z-score <5) .(appendix table v). It was also observed that only 43 out of 53 modules 
were strongly preserved between the cohorts (summary Z-score > 10). Table 4 and Figure 
7shows the module preservation profile for bevacizumab treated stage-IV. 
 
Table 4: Module preservation of bevacizumab treated stage-IV patients with respect to 
bevacizumab treated stage-III and cetuximab cohort 
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Module color Module preservation with Bevacizumab 
treated stage-III 
Module preservation with 
Cetuximab treated patients 
Bisque4 47 47 
Black 7 7 
Blue 2 2 
Brown 3 3 
Brown4 46 46 
Cyan 14 14 
Darkgreen 22 22 
Darkgrey 24 24 
Darkmagenta 34 34 
Darkolivegreen 33 33 
Darkorange 26 26 
Darkorange2 45 45 
Darkred 21 21 
Darkslateblue 48 48 
Darkturquoise 23 23 
Floralwhite 44 44 
Green 5 5 
Greenyellow 11 11 
Grey60 17 17 
Ivory 43 43 
Lightcyan 16 16 
Lightcyan1 42 42 
Lightgreen 18 18 
Lightsteelblue1 41 41 
Lightyellow 19 19 
Magenta 9 9 
mediumpurple3 40 40 
Midnightblue 15 15 
Orange 25 25 
17 
 
Orangered4 39 39 
Paleturquoise 31 31 
Pink 8 8 
Plum1 38 38 
Plum2 49 49 
Purple 10 10 
Red 6 6 
Royalblue 20 20 
Saddlebrown 29 29 
Salmon 13 13 
Salmon4 NA NA 
Sienna3 35 35 
Skyblue 28 28 
Skyblue3 37 37 
Steelblue 30 30 
Tan 12 12 
Thistle1 NA NA 
Thistle2 50 50 
Turquoise 1 1 
Violet 32 32 
White 27 27 
Yellow 4 4 
Yellowgreen 36 36 
 
18 
 
 
 
Figure 7: Preservation z-summary and preservation median rank for the modules of 
bevacizumab treated stage-IV CRC patients 
 
Cetuximab treated CRC patients:  For this cohort of patients, it was found that all the 
modules  were shown to have well defined counterparts  with bevacizumab treated stage-III 
patients' cohorts(summary Z-score>5), while only six modules out of eight were showing  
preservation with bevacizumab treated patients cohort (Z-score >5) (appendix table vi). Table 5 
and Figure 8 shows the module preservation profile for cetuximab treated patients. 
 
Table 5: Module preservation of Cetuximab treated patients with respect to bevacizumab 
treated stage-III and Bevacizumab treated stage-IV cohort 
Module color Module preservation with 
Bevacizumab treated stage-III 
Module preservation with 
Bevacizumab treated stage-IV 
Black 7 7 
Blue 2 2 
Brown 3 3 
Green 5 5 
Red 6 6 
Turquoise 1 1 
Yellow 4 4 
Preservation Median Rank Preservation Zsummary
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Figure 8: Preservation z-summary and preservation median rank for the modules of 
cetuximab treated CRC patients 
 
Step 5: Module selection - To reduce the complexity  only top three modules with highest 
correlation value were selected for further study. For each cohort selected modules , their size 
range and correlation values are summarized in Table 6.  
 
Table 6: Shows selected modules, modules size and their correlation values 
 
Patients cohort Module color Module size Correlation value 
Bevacizumab treated 
stage-III 
Pink 
Yellow 
Brown 
43 
135 
339 
0.88 
0.53 
0.48 
Bevacizumab treated 
stage-IV 
Mediumpurple3 
DarkRed 
Yellow 
57 
144 
530 
0.94 
0.63 
0.62 
Cetuximab treated 
patients 
Blue 
Brown 
Red 
1822 
1860 
1218 
0.99 
0.67 
0.66 
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Step 5.a: Identification of TFs -  gProfiler was applied to identify TFs of selected 
module of the three cohorts and TF related genes were identified by using Uniprot database. 
Figure 9 and Figure 10 shows the overlap between TFs across modules of each cohort and TF 
overlapping across all three patients' cohort .  
 
 
Figure 9: Common TFs among selected modules (A) Venn diagram of common TFs of bevacizumab 
treated stage-III cohort (B) Venn diagram of common TFs of cetuximab treated patients, (C) Venn 
diagram of common TFs of Cetuximab treated patients 
 
It was observed that each modules consists of large number of TFs. iRegulon a cytoscape plug in 
was used to indentify most significant TFs for each modules. iRegulon ranked the significant 
TFs on the basis of enrichment score.  
Table 7, Table 8 and Table 9 shows the significant TFs of selected modules of each patient 
cohort. Top three TFs in each modules were further analyzed for their significance in CRC.  
 
Table 7: Significant TFs for selected modules of bevacizumab treated stage-III patients 
Modules  TF Enrichment score 
Brown  ATF3 4.53 
SP2 4.50 
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ELK1 3.98 
MEF2A 3.88 
ELF3 3.86 
YOD1 3.6 
STAT5A 3.39 
IRF5 3.35 
GABPA 3.31 
Pink  EP300 6.7 
STAT6 5.94 
ZNF652 5.58 
IRF1 4.29 
PRDM1 4.13 
MEF2C 4.11 
EBF1 4.10 
MEF2A 3.7 
YY1 3.66 
USF1 3.45 
Yellow  HNF4A 4.85 
BRF1 4.27 
GRHL1 4.12 
STAT5A 3.80 
GMEB1 3.73 
POLR3A 3.71 
ELF1 3.70 
GATA1 3.44 
MEF2A 3.40 
 
Table 8: Significant TFs for selected modules of bevacizumab treated stage-IV patients 
Modules TF Enrichment score 
DarkRed RFX5 5.31 
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USF2 3.58 
JUN 3.43 
ELF1 3.38 
STAT1 3.36 
NKX3-2 3.35 
PITX3 3.34 
POU5F1 3.29 
EGR1 3.21 
IRF1 3.19 
Mediumpurple CEBPB 4.44 
TAF1 4.36 
YY1 3.98 
CCNT2 3.50 
TGIF2 3.49 
JUND 3.28 
NRF1 3.24 
IRF5 3.20 
CYB5R1 3.10 
SREBF1 3.04 
Yellow IRF1 3.72 
ELF1 3.10 
STAT1 3.08 
TEAD1 3.05 
PAX3 3.04 
ETV6 3.01 
CRX 3.00 
SOX14 2.99 
ASAP3 2.98 
 
Table 9: Significant TFs for selected modules of Cetuximab treated  patients 
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Modules TF Enrichment score 
Blue GABPA 3.78 
TP53 3.06 
YY1 3.03 
GATA1 3.02 
ESRRB 3.01 
FOXA3 3.00 
Brown NFIC 4.51 
SPI1 4.40 
CEBPB 3.25 
ZNF354 3.24 
RHOXF1 3.23 
Red E2F4 5.90 
BRCA1 4.96 
CEBPB 3.73 
UBTF 3.49 
KAT2A 3.25 
MYC 3.24 
POLR2A 3.07 
NR3C1 3.07 
USF1 3.04 
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Figure 10: Venn diagram for common TFs among all three patients cohorts 
 
On TFs analysis  it was observed that only two TFs were common among bavacizumab treated 
stage-III patients and bevacizumab treated stage- IV patients, one  TF was common between  
bevacizumab treated stage-III and cetuximab treated patients and  nine TFs was common among 
bevacizumab treated stage-IV and cetuximab treated patients. .  
 
Step 5.b Pathway analysis of  TFs -  Pathway analysis was performed for all TFs of 
selected modules in each of the three cohorts, It was observed  that three most significant 
pathways across all cohort are as : (i)  transcriptional mis-regulation, (ii) pathways in cancer and 
(iii)  MAPK signaling pathway.   
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Table 10 shows the pathway analysis result for each of the three cohort. 
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Table 10: Pathway analysis result for TFs for all the three cohort 
 
5.c : Visualizing the gene network - Further, genes of selected modules for each of the 
cohort were exported in cytoscape and networks were generated for all the three cohorts. Figure 
11 shows the network of brown, yellow and pink  module of bevacizumab treated stage-III 
module. 
 
  
 
Figure 11: Network of Brown, yellow and pink module of bevacizumab treated stage-III 
CRC patients 
 
 
  
Cohorts Pathway Number of 
TFs 
TFs 
Bevacizumab stage-III Transcriptional mis-
regulation in cancer 
5 CEBPA, RARA, RXRA, SP1, 
TFE3 
Pathways in cancer 2 EP300,  STAT5A 
MAPK signaling pathway 2 ELK1,   MEF2C 
Bevacizumab stage-IV Transcriptional mis-
regulation in cancer 
4 CNT2, CEBPB, ETV6, PAX3 
Pathways in cancer 2 JUN, STAT1 
MAPK signaling pathway 2 JUN, JUND 
Colorectal cancer genes 1 JUN 
Cetuximab Stage-IV Transcriptional mis-
regulation in cancer 
4 CEBPB, MYC, SPI1, TP53 
Pathways in cancer 3 MYC, SPI1, TP53 
MAPK signaling pathway 2 MYC, TP53 
Colorectal cancer genes 2 MYC, TP53 
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
 
Discussion 
A total of 30 gene expression samples belonging to three different treatment regime and control 
were downloaded from the GDC website. A large number of DE genes (p-value <0.001) were 
identified for both bevacizumab-IV and cetuximab treated patients cohorts ( 10,817 and 14,590 
respectively). Whereas only 2,724 DE genes were identified for bevacizumab treated stage-III 
cohort. A total of 6,732 DE genes overlapped between bevacizumab-IV and cetuximab treated 
patients cohorts. A total of 2,184 DE genes were common across bevacizumab treated stage-III, 
bevacizumab treated stage-IV and cetuximab treated patients' cohort. Additionally, 44 genes 
were common in between bevacizumab treated stage-III and bevacizumab treated stage-IV 
cohort and 436 genes were common to bevacizumab treated stage -III and cetuximab treated 
patients' cohort. Each cohort has unique DE genes 60, 1852 and 5229 for bevacizumab stage-III, 
bevacizumab stage-IV and Cetuximab treated cohort respectively. This shows that the DE genes 
profiles are common as well as unique to each treatment regime.  
.Co-expression module analysis was performed for three different cohort and it was hypothesized 
that tightly co-expressed gene modules, enriched in shared functional annotation, would provide 
the most fruitful predictions of candidate gene. Co-expression networks heatmap were generated 
using WGCNA function. In the heatmap, high co-expression interconnectedness is indicated by 
progressively more saturated yellow and red colors (Figure 3). Number of modules were 
identified for bevacizumab treated stage-III, bevacizumab treated stage-IV and cetuximab treated 
patient cohorts was nine, 53 and eight with their size ranges  from 46-734, 30-968 and 1101-
3860 respectively. Some modules have large number of genes , some have small number of 
genes indicating modules size varies across and between the cohorts. On evaluating the modules 
preservation across all the cohorts, it was observed that for  bevacizumab treated stage-III CRC 
patients, all the modules are preserved across other two cohort (Z-summary>5), while in the case 
of bevacizumab treated stage-IV patients(52 modules),  only 47 modules are preserved(Z-
summary>5). module preservation was performed for each cohort with respect to other two 
remaining cohort.  This indicates that bevacizumab treated stage-IV patients have high number 
of DE genes and as a result the modules with this late DE genes are not identified in early stage. 
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For cetuximab treated CRC patients all the seven modules were preserved within and between 
the cohort. The modules identified were analyzed for their correlation with CRC. Each modules 
was annotated with its correlation score computed by WGCNA. The top three high correlation 
value modules were used for further analysis,  i.e.,  to understand their significance in CRC. The 
modules were annotated with colors and scores.  
From the literature, it is known that TFs play an important role in CRC. On analyzing top three 
modules of each cohort, it was identified that each of these modules consist of large number of 
genes. As for each of the cohort, module consists of large number of genes , to reduce the 
complexity the TFs in these cohort were further analyzed for their significance in CRC.  It was 
observed that there was very less overlap between TFs of top three modules in each cohorts 
depicting that these modules were unique in content of TFs and consecutively showing the 
different treatment regime. iRegulon was used to rank the TFs in context of their enrichment 
score and targets. Using literature top three TFs from each modules were further analyzed for 
their correlation in CRC.  
Table 11 shows the top three TFs and their association with CRC for each cohort.  
The TFs were also analyzed for their pathway enrichment. It was observed that TFs in all these 
modules enriched in well known CRC pathways as well as some unique pathways. The common 
CRC pathways enriched were; transcriptional mis-regulation in cancer, pathways in cancer and 
MAPK signaling pathway. Top three pathways and related TFs  are reported in the Table 10 . 
When TFs were analyzed in respect of colorectal cancer, it was found that only one TF (JUN) is 
associated with CRC pathway for bevacizumab treated stage- IV patients. In addition to that JUN  
was also associated with other pathways such as: pathways in cancer and MAPK signaling 
pathway for bevacizumab treated stage-IV patients.  JUN is a proto-oncogene which produce c-
jun protein. Over-expressed c-jun act as an oncogene [44]. It  increase the angiogenic activity of 
tumor cells, by increasing expression of a positive regulator of angiogenesis, such as VEGF, by 
decreasing expression of an angiogenesis inhibitor, such as thrombospondin-1, or by both 
mechanisms [45]. Therefore, targeting c-Jun could be candidates for novel angiogenesis 
inhibitors for use in cancer or in other angiogenesis-dependent diseases, such as macular 
degeneration or psoriasis. Further, for cetuximab tretaed stage-IV patients, only two TFs( MYC 
and TP53) are associated with CRC pathway and these two TFs are also associated with other 
pathways such as: transcriptional mis-regulation, pathways in cancer and MAPK signaling 
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pathway. Myc is a proto oncogene , contributes to the genesis of many human cancer. It activates 
the transription of growth related genes. Its expression and function have led to new cancer 
therapeutic opportunities.  Myc's activation could be inhibited by drug-like molecules, resulting 
in tumor inhibition in vivo [46]. Therefore, it could be a potent new biomarker for CRC patients. 
On contrary, no CRC associated TFs were identified for bevacizumab treated stage-III patients. 
Most probably it is due to lesser number of mutated genes in stage-III patients in comparison to 
stage-IV patients. On pathways analysis of TFs, it was observed that CEBPs were common 
among all the patient cohort. C/EBPs are DNA binding proteins. The CEBP encoded proteins are 
essential for terminal differentiation and functional maturation of granulocyte progenitor cells. 
The main function of CEBPB are the regulation of expression of genes involves in immune and 
inflammatory response[47]. So, CEBP could also be a new biomarker for CRC.  
Table 11 shows that each treatment regime identified TFs known to be involved in CRC and in 
other cancers.  In addition, each treatment regime also identified new TFs that can be further 
validated in labs(wet-lab) such as: (i) for bevacizumab stage-III patients, top known TFs in CRC 
are [EP300, STAT6,ATF3,SP2 and HNFA]. The new TFs that are not validated as biomarker or 
reported in CRC are (ELK1 and GRHL1). (ii) for bevacizumab stage-IV patients, the known TFs 
in CRC are RFX5,IRF1, STAT1 and ELF1. The new TFs which could be potent biomarker are 
CEBPs, YY1 and JUN.(iii) for cetuximab treated patient cohort, known TFs are TP53 and  E2F4. 
The new TFs are GABPA, YY1, NFIC, BRCA1 and CEBPE.  
 
Table 11: Significant TFs function and their association with cancer 
Bevacizumab treated stage-III patients 
Module 
color 
TFs Function Cancer Biomarker 
Pink EP300 Regulates transcription via chromatin 
remodeling and important in the processes 
of cell proliferation and differentiation. It is  
a co-activator of HIF1A (hypoxia-inducible 
factor 1 alpha), and thus plays a role in the 
stimulation of hypoxia-induced genes such 
as VEGF [48]. Diseases associated with 
EP300 include Rubinstein-Taybi 
syndrome2 and Colorectal cancer [49]. 
CRC 
Stomach 
Breast 
Pancreas 
Prostrate 
 
Yes 
STAT6  Promote proliferation and inhibit 
apoptosis. STAT6 is over-expressed and 
active in numerous malignancies including 
CRC, Breast 
Glioblastoma 
Urothelial 
Yes 
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prostate and colon cancer [50]. Lymphoma 
Prostrate 
ZNF652 A transcriptional repressor protein. It 
directly  repressed key drivers of invasion 
and metastasis, such as TGFB1, TGFB2, 
TGFBR2, EGFR, SMAD2 and VIM. Loss 
of ZNF652 expression in primary breast 
tumors was significantly correlated with 
increased local invasion and defined a 
population of breast cancer patients with 
metastatic tumors [51] . 
Breast 
Melanoma 
Endometrial 
Thyroid 
New? 
Brown ATF3 ATF3 up regulates the expression of 
several genes in the tumor necrosis factor 
pathway in cancer development [52]. Up 
regulation of ATF3 in lung cancer 
promotes cell proliferation, migration, and 
invasion, and may represent a novel 
therapeutic target for lung cancer [53]. 
ATF3 may play a dichotomous role in 
apoptosis and metastasis in human 
colorectal cancer cells [54] . 
Colon 
Breast 
Lung 
Pancreas 
 
Yes 
SP2 Over expression of  Sp2 Inhibits Epidermal 
Differentiation and Increases Susceptibility to 
Wound- and Carcinogen-Induced Tumor 
genesis [55]. Sp family proteins are required 
for endogenous expression of VEGF in 
pancreatic cancer cells. COX-2 inhibitors 
and other nonsteroidal anti-inflammatory 
drugs (NSAIDs) inhibit development and 
growth of colon cancer by down regulating 
sp-proteins. COX-2 inhibitors decreased 
VEGF protein, mRNA, and reporter gene 
expression, and this was accompanied by 
down-regulation of both Sp1 and Sp4 but 
not Sp3 or Sp2 proteins [56]. 
 
Colon 
Carcinoid 
Ovarian 
Stomach 
 
Yes 
ELK1 It forms a ternary complex by binding to 
the serum response factor and the serum 
response element in the promoter of the c-
fos proto-oncogene. The protein encoded 
by this gene is a nuclear target for the ras-
raf-MAPK signaling cascade. 
Colon 
Breast 
Prostrate 
Gastric  
 New? 
Yellow HNF4A It is expressed in the liver, pancreas, 
kidney, stomach, small intestine and colon, 
where it regulates many important aspects 
of epithelial cell morphogenesis and 
function. HNF4α plays a protective role 
against inflammatory bowel disease, an 
important risk factor for colorectal cancer 
[57]. 
CRC 
Liver 
Stomach 
Yes 
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BRF1 Brf1 (TFIIB-related factor 1) plays a 
crucial role in cell transformation and 
tumorigenesis.  Brf1 is a new biomarker of 
heptocellular carcinoma(HCC) [58]. 
Germline mutations in BRF1 associated 
with predisposition to CRC [59]. 
Prostrate 
Heaptocellular 
carcinoma 
(HCC) 
 
GRHL1  .GRHL1 is a tumor suppressor in the 
squamous cell carcinoma (SCC) of the 
skin. GRHL proteins play important role in 
cancer development [60].  
Skin  
Cervical 
Urethral  
New? 
Bevacizumab tretaed stage-IV 
Module color TFs Function Cancer Biomarker 
Darkred RFX5  RFX5 mutations were related to lack of or 
faint HLA class II antigen expression IN 
CRC. Somatic mutations of the RFX5 gene 
represent a novel mechanism of loss of 
HLA class II antigen expression in tumor 
cells, potentially contributing to immune 
evasion in MSI-H CRCs [61]. 
CRC 
Endometrial 
Lymphoma 
Stomach 
Lungs 
Head and neck 
Yes 
USF2 It regulates cellular growth and 
proliferation.  USF2 involves in  prostate 
tumorigenesis [77]. USF2 associated with 
reoccurrence of CRC [62].  
Breast 
Lung 
ovarian 
New? 
JUN c-Jun potentially plays an important role in 
carcinogenesis and cancer progression. c-
Jun activation is associated with 
proliferation and angiogenesis in invasive 
breast cancer [63]. Jun protein family levels 
has been reported higher in CRC patients 
[64].  
 
CRC, Breast, 
Prostrate, Skin 
Lung, Ovarian 
Bladder 
 
New? 
Mediumpurple CEBP (C/EBPs) are a family of  leucine-zipper 
TFs that regulate gene expression to control 
cellular proliferation, differentiation, 
inflammation and metabolism. Encoded by 
an intronless gene. C/EBP-β-activated miR-
223 contributes to tumor growth by 
targeting RASA1 in CRC and miR-223-
targeted inhibitors may have clinical 
promise for CRC treatment via suppression 
of miR-223[65]. 
CRC 
Liver 
Lung 
Testis 
 
New? 
TAF1 It encodes a protein that functions as a 
transcriptional co-activator. The protein is 
also involved in the recognition of 
transcriptional promoters and the 
modification of general transcription 
factors (GTFs). 
Breast 
CRC 
Renal 
Liver 
 
New? 
YY1 Yin Yang 1 (YY1) is highly expressed in 
various types of cancers and regulates 
tumor genesis through multiple pathways. 
Breast 
Prostrate 
CRC 
New? 
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YY1 is generally over expressed in breast 
cancer cells and tissues. Yin Yang 1 plays 
an essential role in breast cancer and 
negatively regulates p27 [66]. Role of YY1 
in repression of dominant negative LEF-
1(Lymphoid enhancer factor 1) expression 
in colon cancer [67]. 
 
Yellow IRF1 Some tumors escape the antitumor effects 
of IFN-gamma by cellular changes 
reflected in IRF-1 and IRF-2 expression. 
IRF-1 expression is consistent with its role 
as a tumor suppressor [68]. IRF1 involves 
in CRC tumorigenesis. A positive feedback 
loop between IRF1 and miR-29b may 
contribute to the sensitivity of CRC cells to 
IFN-γ [69]. 
Breast 
Stomach 
Cervical 
CRC 
Yes 
STAT1 Transcription factors STAT3 and STAT1, 
both downstream effectors of interleukin 
(IL)-6 and its receptor, are involved in 
growth and developmental control of CRC 
cells [70]. 
CRC 
Melanoma 
Breast 
Skin 
Yes 
ELF1 It involved in cellular growth and 
differentiation. Enhanced expression of Elf-
1 has been reported in prostate cancer, 
breast cancer, and osteosarcoma [71]. Ets 
factors show altered expression in colon 
cancer, where they regulate pathways 
relevant to tumor progression [72]. 
CRC 
Breast 
Pancretic 
Skin 
Yes 
Cetuximab treated patients 
Module color TFs Function Cancer Biomarker 
for CRC 
Blue GABPA  It involved in activation of cytochrome 
oxidase expression and nuclear control of 
mitochondrial function. Abnormal 
expression of GABPA is associated with 
tumor development and progression[73]. 
GABP is essential for eIF6 promoter 
activity which indicates GABP is a global 
regulator of ribosome biosynthesis. 
Carcinoid 
Heaptocellular 
Breast 
CRC 
New? 
TP53 Somatic TP53 mutations occur in almost 
every type of cancer at rates from 38%–
50% in ovarian, esophageal, colorectal, 
head and neck, larynx, and lung cancers to 
about 5% in primary leukemia, sarcoma, 
testicular cancer, malignant melanoma, and 
cervical cancer[74]. 
Ovarian 
Esophagal 
CRC 
Breast 
Head and neck 
Melanoma 
cervical 
Yes 
YY1 Yin Yang 1 (YY1) is highly expressed in 
various types of cancers and regulates 
tumor genesis through multiple pathways. 
Breast 
Prostrate 
CRC 
New? 
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YY1 is generally over expressed in breast 
cancer cells and tissues. Yin Yang 1 plays 
an essential role in breast cancer and 
negatively regulates p27 [66]. 
Brown NFIC Downstream factors of NFI-C, such as 
KLF4 and E-cadherin  play roles in 
epithelial-to-mesenchymal transition 
(EMT).  NFI-C is expressed in normal 
mammary gland or noninvasive breast 
cancer cells. NFI-C play important role in 
regulating KLF4 during tumorigenesis [75]. 
NFIC also involved in CRC [76]. 
Breast 
Stomach 
Endometrial 
CRC 
Ovarian 
New? 
SPI1 Activates gene expression during myeloid 
and B-lymphoid cell development. The 
nuclear protein binds to a purine-rich 
sequence known as the PU-box, and 
regulates their expression in coordination 
with other transcription factors and 
cofactors. 
Glioma 
Lung 
Stomach 
Lymphoma 
pancreatic 
New? 
CEBPE C/EBPs) are a family of  leucine-zipper 
transcription factors that regulate gene 
expression to control cellular proliferation, 
differentiation, inflammation and 
metabolism. Encoded by an intronless 
gene. Its related pathways are 
transcriptional mis-regulation [77]. 
CRC 
Liver 
Lung 
Testis 
 
Yes 
Red E2F4 E2F4 expression slowed down G1/S phase 
transition and the proliferation rate of 
normal human intestinal epithelial cells 
(HIEC) and of colon cancer cells[78]. 
Breast 
CRC 
Prostrate 
Lung 
Yes 
BRCA1 BRCA1 predicted survival in all colorectal 
cancer patients. Low expression of BRCA1 
was associated with loss of MLH1 or 
MSH2 expression[79]. BRCA1 is a TF 
involved in CRC[76] . 
Breast 
Prostrate 
Ovarian 
CRC 
New? 
CEBPE C/EBPs) are a family of leucine-zipper 
transcription factors that regulate gene 
expression to control cellular proliferation, 
differentiation, inflammation and 
metabolism. Encoded by an intronless 
gene. Its related pathways are  
transcriptional mis-regulation [80]. 
CRC 
Liver 
Lung 
Testis 
 
Yes 
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Conclusion 
This brief analysis shows that different treatment regime do target some common and known 
CRC related genes and TFs . But at the same time they are unique in context of their targets. It 
also underlies the knowledge that there are genotypical variation in cancer across the patient. It is 
essential to identify the patient profile initially and then go for right target for particular patient. 
The above analysis shows that though there is overlap between the DEs across the different 
regimes, still each of the regimes are unique in their context which is showing a clear necessity 
for targeted treatment for right patient.  
 
 
 
 
  
35 
 
Supplementary Files 
 
a) Differentially expressed transcripts for each of the cohorts i.e bevacizumab treated 
patients ( stage-III and Stage-IV) and Cetuximab treated CRC patients. 
b) Gene significance and Gene module membership for all three cohorts. 
c) GO Enrichment Analysis result of all three cohorts. 
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Appendix 
 
 
 
Appendix figure i : Scale free topology for co-expression network of patients treated with 
cetuximab  
 
Table i : Modules color and size of 14 identified modules for bevacizumab treated stage-III 
CRC patients 
Module color Module size 
Pink 
Magenta 
Red 
Black 
Green 
Yellow 
Brown 
Blue 
turquoise 
 
43 
44 
88 
91 
95 
135 
339 
510 
682 
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Table ii : Module color and size of 53 identified modules of bevacizumab trated stage-IV 
CRC patients 
Module color Module size 
Grey  
salmon4  
thistle1 
darkslateblue  
plum2  
thistle2 
bisque4  
darkorange2  
floralwhite  
brown4  
Ivory  
lightcyan1  
plum1  
orangered4  
lightsteelblue1  
mediumpurple3  
skyblue3  
yellowgreen  
darkmagenta  
darkolivegreen 
steelblue  
Violet  
sienna3  
paleturquoise  
skyblue  
orange  
saddlebrown  
1 
23 
24 
28 
33 
33 
36 
36 
36 
38 
39 
48 
49 
53 
54 
57 
58 
60 
64 
66 
67 
68 
69 
76 
79 
82 
82 
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White  
darkorange  
darkgrey  
darkturquoise  
darkgreen  
darkred  
royalblue  
grey60  
lightgreen  
lightyellow  
lightcyan  
midnightblue  
Cyan  
Tan  
salmon  
greenyellow  
Purple  
Pink  
magenta  
Black  
Red  
Green  
Brown  
Yellow 
Blue  
turquoise  
89 
91 
114 
127 
135 
144 
150 
174 
179 
179 
185 
204 
217 
223 
236 
278 
294 
307 
310 
378 
385 
429 
526 
530 
566 
843 
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Table iii : Seven identified modules of cetuximab trated CRC patients 
 
Module color Module size 
Black 
Red 
Green 
Yellow 
Blue 
Brown 
turquoise 
916 
1218 
1392 
1723 
1822 
1860 
3301 
 
Table iv: Bevacizumab treated stage-III patients module preservation Z-summary 
 
Bevacizumab stage-III and Cetuximab: 
 
              
Bevacizumab stage-III to Bevacizumab stage-IV: 
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Table v : Bevacizumab treated stage-IV module preservation Z-summary 
 
Bevacizumab stage-IV and Cetuximab 
 
                    medianRank.pres medianRank.qual Zsummary.pres Zsummary.qual 
bisque4                      12             1.0          17.0            27 
black                        52            22.0           1.6            72 
blue                         51            49.5           4.9            73 
brown                        16            50.5          78.0            75 
brown4                       36            10.0          10.0            22 
cyan                         24            21.0          42.0            64 
darkgreen                    23            29.5          32.0            45 
darkgrey                     43            40.0          15.0            43 
darkmagenta                  19            15.0          21.0            34 
darkolivegreen               12            45.0          28.0            28 
darkorange                    1            13.5          33.0            48 
darkorange2                  11             4.0          16.0            30 
darkred                      21            42.0          32.0            38 
darkslateblue                49            13.5           1.9            21 
darkturquoise                35            23.5          26.0            48 
floralwhite                  41            32.0           9.1            21 
gold                         48            53.0          18.0            -1 
green                        48            46.0           7.4            73 
greenyellow                  38            43.0          40.0            58 
grey                         NA              NA           NaN            NA 
grey60                       31            49.5          32.0            37 
ivory                        47            41.0           2.3            20 
lightcyan                    34            37.5          31.0            46 
lightcyan1                   21            16.0          16.0            32 
lightgreen                   28            33.0          34.0            53 
lightsteelblue1              45            31.0           7.1            24 
lightyellow                  31            48.0          30.0            39 
magenta                       6            25.0          60.0            74 
mediumpurple3                45            11.0           8.1            33 
midnightblue                 42            44.0          26.0            48 
orange                       50            28.5           2.1            33 
orangered4                   17            20.5          20.0            26 
paleturquoise                33            47.0          18.0            26 
pink                         15            27.5          61.0            76 
plum1                        39            39.0          14.0            26 
plum2                         4             3.0          15.0            22 
purple                       37            37.0          38.0            61 
red                           7            36.5          63.0            69 
royalblue                     5            19.5          46.0            47 
saddlebrown                  31            17.0          19.0            38 
salmon                       39            52.0          28.0            50 
salmon4                      28             2.0           8.9            25 
sienna3                       9             5.0          24.0            35 
skyblue                      15            34.5          24.0            30 
skyblue3                     18            12.0          20.0            33 
steelblue                    24            23.5          20.0            32 
tan                          29            37.0          37.0            56 
thistle1                      3             6.5          15.0            23 
thistle2                      8             8.5          16.0            22 
turquoise                    13            28.5         110.0           110 
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violet                       19             8.5          21.0            37 
white                         2             6.5          29.0            41 
yellow                       47            26.5          14.0            85 
yellowgreen                  23            18.0          19.0            32 
 
Bevacizumab stage-IV to Bevacizumab stage-III 
               medianRank.pres medianRank.qual Zsummary.pres Zsummary.qual 
bisque4                      13             1.0         16.00          30.0 
black                        52            20.0          1.40          99.0 
blue                         51            51.0          5.00          76.0 
brown                        17            47.0         87.00          83.0 
brown4                       35            10.0         12.00          25.0 
cyan                         23            22.5         42.00          63.0 
darkgreen                    24            32.5         33.00          45.0 
darkgrey                     43            40.5         15.00          36.0 
darkmagenta                  20            16.0         21.00          37.0 
darkolivegreen               12            44.0         28.00          28.0 
darkorange                    1            14.0         33.00          46.0 
darkorange2                  12             4.0         17.00          31.0 
darkred                      23            40.5         35.00          44.0 
darkslateblue                51            11.0          0.45          21.0 
darkturquoise                34            24.0         25.00          47.0 
floralwhite                  41            32.0          9.50          21.0 
gold                         46            53.0         25.00          -1.3 
green                        49            46.0          8.70          78.0 
greenyellow                  38            43.0         39.00          60.0 
grey                         NA              NA           NaN            NA 
grey60                       30            50.0         36.00          40.0 
ivory                        47            41.5          2.50          22.0 
lightcyan                    33            38.0         38.00          53.0 
lightcyan1                   21            17.5         17.00          27.0 
lightgreen                   28            32.0         36.00          55.0 
lightsteelblue1              44            28.5          8.90          28.0 
lightyellow                  32            49.0         34.00          42.0 
magenta                       7            25.0         63.00          79.0 
mediumpurple3                45            12.0          7.40          36.0 
midnightblue                 42            45.0         29.00          51.0 
orange                       51            27.0          1.80          40.0 
orangered4                   16            21.0         22.00          30.0 
paleturquoise                36            48.0         18.00          27.0 
pink                         15            30.5         68.00          81.0 
plum1                        39            39.0         15.00          31.0 
plum2                         3             3.0         18.00          28.0 
purple                       37            37.0         39.00          69.0 
red                           7            34.5         69.00          81.0 
royalblue                     5            17.0         48.00          56.0 
saddlebrown                  32            15.0         21.00          39.0 
salmon                       39            52.0         32.00          46.0 
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salmon4                      29             2.0          8.60          24.0 
sienna3                       9             5.5         25.00          38.0 
skyblue                      14            35.5         30.00          33.0 
skyblue3                     19            13.0         21.00          35.0 
steelblue                    26            23.5         22.00          39.0 
tan                          27            34.5         43.00          68.0 
thistle1                      5             7.0         15.00          27.0 
thistle2                      8             8.0         17.00          28.0 
turquoise                    11            28.5        120.00         130.0 
violet                       19             9.0         22.00          42.0 
white                         2             5.5         34.00          52.0 
yellow                       47            26.0         14.00         100.0 
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Table vi: Cetuximab treated CRC patients module preservation Z-summary 
 
Cetuximab to Bevacizumab stage-III 
            medianRank.pres medianRank.qual Zsummary.pres Zsummary.qual 
black                 2.5               3            74        120.00 
blue                  5.0               5            79        150.00 
brown                 3.0               2            88        150.00 
gold                  8.0               8            34          0.41 
green                 1.0               1            87        160.00 
red                   6.0               6            70        120.00 
turquoise             6.0               7            75        130.00 
yellow                4.0               4            82        140.00 
 
Cetuximab to Bevacizumab stage-IV 
 
           medianRank.pres medianRank.qual Zsummary.pres Zsummary.qual 
black                   7               3           1.7        120.00 
blue                    1               5          23.0        150.00 
brown                   2               2          13.0        150.00 
gold                    5               8           2.1          0.41 
green                   5               1          11.0        160.00 
red                     4               6           7.3        120.00 
turquoise               3               7           7.0        130.00 
yellow                  6               4           7.3        140.00 
 
 
Table vii : Modules and their correlation values for bevacizumab treated stage-III patients 
Module color Correlation value 
Pink 
Magenta 
Red 
Black 
Green 
Yellow 
Brown 
Blue 
turquoise 
0.88 
0.19 
-0.48 
0.05 
0.15 
0.53 
0.48 
0.07 
-0.39 
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Table viii:Modules and their correlation values for bevacizumab treated stage-IV patients 
Module color Correlation value Module color Correlation value 
Brown4 
Plum1 
Darkgrey 
Lightsteelblue1 
Tan 
Skyblue 
Orangered4 
Lightcyan1 
Orange 
White 
Black 
Midnightblue 
Darkorange 
Salmon4 
Violet 
Plum2 
Darkorange2 
Thistle1 
Steelblue 
Darkolivegreen 
Yellowgreen 
-0.754 
-0.576 
-0.46 
-0.44 
-0.41 
-0.359 
-0.331 
-0.256 
-0.248 
-0.162 
-0.101 
-0.069 
-0.057 
-0.045 
-0.001 
0.014 
0.024 
0.061 
0.124 
0.184 
0.301 
Greenyellow 
Pink 
Saddlebrown 
Skyblue3 
Lightyellow 
Grey60 
Brown 
Magenta 
Red 
Green 
Salmon 
Darkturquoise 
Darkgreen 
Royalblue 
Ivory 
Cyan 
Grey 
Bisque4 
Turquoise 
Floralwhite 
Darkslateblue 
-0.631 
-0.49 
-0.441 
-0.425 
-0.389 
-0.334 
-0.277 
-0.249 
-0.183 
-0.153 
-0.094 
-0.063 
-0.052 
-0.021 
0.007 
0.019 
0.036 
0.099 
0.177 
0.262 
0.304 
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Thistle2 
Purple 
Darkmagenta 
Sienna3 
Paleturquoise 
Mediumpurple3 
0.318 
0.35 
0.386 
0.439 
0.63 
0.943 
Lightcyan 
Blue 
Lightgreen 
Darkred 
Yellow 
0.339 
0.365 
0.407 
0.584 
0.62 
 
Table ix :Modules and their correlation values for cetuximab treated  patients 
 
Module color Correlation value 
Green 
Blue 
Brown 
Black 
Yellow 
Red 
Turquoise 
-0.31 
0.99 
0.66 
-0.42 
0.16 
0.67 
-0.28 
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